
As neurotechnology advances, countries and states face increasing pressure to protect neural data. Some have begun turning those concerns into law, from constitutional protections in Chile to amendments to US state privacy legislation. The ability to infer sensitive information from neural signals may expand as scientific knowledge progresses, making the scope of these protections increasingly important.
International bodies including the OECD, UNESCO and the UN have called for stronger protections. Awareness is increasing, but is it translating into enforceable obligations? With recommendations, constitutional rights and data privacy laws developing alongside one another, it can be difficult to distinguish what is already legally protected from what remains a statement of intent. We break it down below.
In 2021, Chile became the first country to enshrine ‘neurorights’—mental privacy, integrity and cognitive liberty—into its constitution. The neuroprivacy ruling followed when the Chilean Supreme Court ordered neurotechnology company Emotiv to delete a user’s neural data over concerns about consent and data protection.
In December 2023, the Brazilian state of Rio Grande do Sul also amended its constitution to recognise mental integrity as a principle governing scientific and technological research. But unlike Chile’s amendment, it made no explicit reference to brain activity or inferences derived from neural data.
At the federal level, Brazil has proposed constitutional protections for mental integrity and neural data through PEC 29/2023. Mexico and Spain have also proposed incorporating neurorights into their national constitutions, although these proposals have yet to be enacted.
Although Chile’s Emotiv ruling demonstrated that neural privacy rights could be enforced, some commentators have questioned how much the constitutional amendment contributed to the outcome. They argue that existing privacy and data protection laws may already have provided sufficient grounds for the ruling, highlighting the importance of translating constitutional principles into specific, verifiable regulatory obligations.
Another approach targets specific activities that capture brain activity. France’s Bioethics Law, introduced in 2011 and amended in 2021, restricts brain imaging to medical, scientific and judicial purposes, requiring explicit, informed and revocable consent. It also introduces safeguards against misuse of brain imaging data and allows authorities to prohibit technologies that modify brain activity and pose serious health risks.
In the US, neural data protection has largely developed through state privacy laws. At the federal level, the proposed MIND Act (2025) would direct the Federal Trade Commission to investigate neural data privacy risks and gaps in existing regulation, but would not itself establish comprehensive protections.
Colorado was the first US state to explicitly protect neural data, passing HB 24-1058 in 2024. The legislation expanded the Colorado Privacy Act’s definition of sensitive data to include biological and neural data, requiring companies to obtain consent before processing it.
California followed later that year with SB 1223, classifying neural data as sensitive personal information under the California Consumer Privacy Act. In September 2026, it enacted AB 1883, restricting employers’ use of AI-powered workplace surveillance tools to collect neural data or infer employees’ emotional states.
Connecticut, Vermont and Delaware also classify neural data as sensitive information, but exclude the peripheral nervous system from their definitions. States therefore differ not only in how they regulate neural data, but in how they define it.
Vermont is one of the more restrictive states, requiring consent and that processing be ‘reasonably necessary’ for the purposes for which the data was collected. Consent alone therefore does not permit unlimited downstream use.
Montana extended its Genetic Information Privacy Act to cover neural data in 2025, an approach echoed by Illinois’ proposed SB2994. These different approaches reflect uncertainty over where neural data belongs, with states treating it as consumer, biometric or genetic information.
Beyond these explicit protections, broader privacy and data broker laws in states such as Oregon, Texas and New Jersey may also cover identifiable neural data. For neurotechnology companies operating across state borders, this patchwork creates compliance challenges, with requirements for collecting, processing and licensing data varying between jurisdictions.
Many of these state laws exempt de-identified neural data. However, growing evidence suggests it may not be possible to fully anonymise neural data such as EEG signals, raising questions about the adequacy of these exemptions.
Recognising the need for neural data protection does not guarantee legislation, a lesson echoed in AI regulation debates. China’s Ethics Guidelines for Brain-Computer Interface Research and Canada’s Principles and Priorities for Responsible Innovation in Neurotechnology, both published in 2024, provide guidance but do not establish legally binding frameworks specific to neural data.
Despite Australia’s growing neurotechnology industry, the country has yet to explicitly protect neural data in legislation. In 2025, the Australian Human Rights Commission published a report on ‘Protecting Cognition’, offering several concrete recommendations for neurotechnology regulation.
India’s Supreme Court has recognised mental and decisional autonomy as aspects of the constitutional right to privacy, potentially providing a foundation for neural data protection, though the link is not explicit. However, the omission of a ‘sensitive personal data’ category from its Digital Personal Data Protection Act represents a potential setback for specific neural data protections.
A 2024 review highlighted concerns over a lack of neurotechnology regulation in many African countries. These gaps can increase the risk of ‘ethics dumping’, where unethical research practices are outsourced to countries with weaker regulatory oversight.
In other cases, legally binding regulations already exist, as with the EU’s GDPR and medical device regulations, but may not adequately address emerging consumer neurotechnology applications. Here, the gap concerns regulatory scope.
A recent industry-led initiative aims to bridge the gap between principles and practice. The World Economic Forum’s Neurotechnology Best Practice Commitments set out expectations for responsible neurotechnology innovation, including informed consent for neural data sharing and transparent data retention policies.
The commitments are accompanied by a ‘Neurotrust Index’, intended to assess companies’ adherence to the pledge. Although voluntary and non-binding, the initiative could represent a shift towards verifiable commitments, something experts have been calling for in neurotechnology regulation.